Dutch human gene therapy specialist uniQure (Nasdaq: QURE) has appointed Charles Richard as senior vice president of research and development in neuroscience.
He will lead the company’s growing portfolio of gene therapies targeting neurological diseases including current clinical trials for Parkinson’s disease and preclinical programs in Huntington’s disease.
Dr Richard joins with 30 years of industry, academic and medical practice experience, and has had a particular focus on rare and orphan diseases. He joins from biotech company Oxyrane, where he was chief medical officer and remains a member of the firm's board of directors.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze